PROTAC Bcl-xL degrader-4

PROTAC Bcl-xL degrader-4 (Compound 2-38-III) is a Bcl-xL PROTAC degrader. PROTAC Bcl-xL degrader-4 has strong anti-tumor activity against HepG2 cells and HUVEC cells. PROTAC Bcl-xL degrader-4 induces cells apoptosis by decreasing mitochondrial membrane potential and activating the MAPK signaling pathway. PROTAC Bcl-xL degrader-4 significantly inhibits tumor growth in xenograft tumor mouse models[1]. Pink: MAPK ligand (HY-176741) ; Blue: CRBN ligase ligand (HY-10984) ; Black: linker (HY-W017440)

Product Specifications

CAS Number

[2930759-37-6]

UNSPSC

12352211

Target

Apoptosis; Bcl-2 Family; ERK; JNK; Mitochondrial Metabolism; p38 MAPK; PROTACs; Reactive Oxygen Species (ROS)

Related Pathways

Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PROTAC; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O=C1N(C(C2=CC=CC(NCCOCCOCCOC(C3=CC4=C(NC(C5=CC=CC6=C5C=CC=C6)=CC4=O)C=C3)=O)=C21)=O)C7CCC(NC7=O)=O

Molecular Formula

C39H34N4O9

Molecular Weight

702.71

References & Citations

[1]Sun G, et al. Protac synthesized on the basis of azaflavonoid derivatives possesses favorable anti-hepatocellular carcinoma activity. Bioorg Chem. 2025 Aug;163:108687.